Travere Therapeutics just saw its modeled fair value per share move slightly, from US$42.36 to US$42.50, in the latest analyst update. That modest shift sits against a backdrop of Street research ...
The latest health news includes calls for transparency in FDA's accelerated drug approvals, expanded use of Travere's kidney drug, Roche's new study for gene therapy, and Hetero's global drug rollout ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...
Travere Therapeutics (TVTX) is back in focus after the U.S. FDA approved FILSPARI as the first and only therapy for focal segmental glomerulosclerosis in certain adults and children, thereby expanding ...
Recent advancements in health news highlight the FDA's approval of Travere's drug for a rare kidney disease, new AI tools for ...
Investor's Business Daily on MSN
Travere Therapeutics sees its composite rating rise to 97
Travere Therapeutics saw an improvement in its IBD SmartSelect Composite Rating Wednesday, from 94 to 97.
Travere Therapeutics stock jumps 37% after the FDA expands Filspari's use to a second rare kidney disease, boosting its market reach and treatment potential.
Filspari is now indicated for patients with focal segmental glomerulosclerosis without nephrotic syndrome to target significant proteinuria reduction.
Travere Therapeutics’ sparsentan receives US FDA nod to treat focal segmental glomerulosclerosis; the first and only approved medicine for FSGS: San Diego Wednesday, April 15, 2 ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results